查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951875

镰状细胞贫血治疗市场分析及预测（至2035年）：按类型、产品类型、技术、应用、最终用户、采用情况、开发阶段、设备和解决方案划分

Sickle-cell Anemia Therapeutics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Deployment, Stage, Device, Solutions
出版日期: | 出版商: Global Insight Services | 英文 388 Pages | 商品交期: 3-5个工作天内

价格
简介目录

镰状细胞贫血治疗市场预计将从2024年的25亿美元成长到2034年的56亿美元，复合年增长率约为10.1%。镰状镰状症状的各种治疗方法，例如基因疗法、输血和药物治疗。基因研究的进步和公众意识的提高是推动该市场成长的主要因素，其重点在于改善患者的治疗效果和生活品质。对更有效、更具针对性的治疗方法的需求正在推动创新治疗方法的发展。

镰状细胞疾病治疗市场正经历强劲成长，这主要得益于基因疗法和药物创新的进步。基因疗法凭藉着针对疾病遗传根源的变革性潜力，引领市场发展。包括 CRISPR-Cas9 在内的基因组编辑技术处于领先地位，预计将提供长期解决方案。製药业也紧随其后，羟基脲和沃克洛託等关键疗法正在帮助患者改善生活品质。 L-麸酰胺酸和单株抗体等新兴治疗方法也日益受到关注，反映出治疗方法的多样化趋势。由于成功率的提高和风险的降低，骨髓移植领域重新焕发活力。同时，包括疼痛管理和输血在内的支持性治疗在患者管理中继续发挥重要作用。远端医疗和病患监测应用程式等数位健康解决方案的整合，正在提高治疗的可及性和药物依从性，从而进一步推动市场成长。不断增加的研究经费和策略合作可望促进创新并拓展治疗选择。

市场区隔
类型 基因疗法、药物疗法、骨髓移植
产品 羟基脲、L-麸酰胺酸、voxelotor、crizanlizumab
科技 CRISPR-Cas9、慢病毒载体、 RNA干扰
适应症 疼痛管理、输血、中风预防、急性胸痛综合征
最终用户 医院、专科诊所、研究机构、居家医疗
实施表格 本机部署、云端部署、混合式部署
实施阶段 临床前研究、临床试验与商业化
医疗设备 输液帮浦、输血设备、诊断设备
解决方案 病患监测、治疗监测、数据分析

镰状细胞疾病治疗市场正经历市场份额、定价策略和产品创新方面的动态变化。製药公司正致力于研发创新治疗方法以满足未被满足的医疗需求，从而形成了一个竞争激烈的市场格局，新产品频繁上市。定价策略日益受到价值导向模式的影响，反映出企业对成本效益和病患疗效的日益重视。北美仍然是市场主导，而新兴地区也受到越来越多的关注和投资。竞争基准分析显示，市场结构以策略联盟和併购为特征，旨在加强产品系列併扩大地域覆盖范围。监管影响至关重要，北美和欧洲严格的监管准则推动了合规性和创新。各公司正利用法规结构来获取竞争优势，并致力于加速新型治疗方法的核准流程。儘管面临研发成本高昂和临床试验流程复杂等挑战，但在基因疗法和个人化医疗的推动下，市场仍呈现成长动能。

主要趋势和驱动因素：

由于人们对镰状细胞疾病的认识不断提高以及治疗方法的进步，镰状细胞疾病治疗市场正经历蓬勃发展。基因疗法的发展是关键趋势之一，它有望永久治癒。这些创新治疗方法正透过临床试验获得广泛认可，并有望为患者带来突破性疗效。另一个重要趋势是製药公司与研究机构之间合作日益密切的。这些伙伴关係正在加速新型疗法的研发，并促进患者更快获得最先进治疗。此外，撒哈拉以南非洲和印度等地区镰状细胞病患疾病率的上升也推动了对有效治疗方法的需求。政府主导的措施和资金投入也在市场扩张中发挥关键作用，改善开发中国家的医疗基础设施和提高治疗可近性的努力创造了新的机会。此外，对个人化医疗的日益重视正在推动标靶治疗的发展，从而改善患者预后并提升市场前景。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 基因治疗
    • 药物治疗
    • 骨髓移植
  • 市场规模及预测：依产品划分
    • 羟基脲
    • L-麸酰胺酸
    • 体素
    • 克里扎利珠单抗
  • 市场规模及预测：依技术划分
    • CRISPR-Cas9
    • 慢病毒载体
    • RNA干扰
  • 市场规模及预测：依应用领域划分
    • 疼痛管理
    • 输血
    • 预防中风
    • 急性胸部综合症
  • 市场规模及预测：依最终用户划分
    • 医院
    • 专科诊所
    • 研究所
    • 居家医疗
  • 市场规模及预测：依发展状况
    • 本地部署
    • 基于云端的
    • 杂交种
  • 市场规模及预测：依阶段划分
    • 临床前阶段
    • 临床试验
    • 已上市
  • 市场规模及预测：依设备划分
    • 点滴帮浦
    • 输血装置
    • 诊断设备
  • 市场规模及预测：按解决方案划分
    • 病患监测
    • 治疗监测
    • 数据分析

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Global Blood Therapeutics
  • Emmaus Life Sciences
  • CRISPR Therapeutics
  • Bluebird Bio
  • Sangamo Therapeutics
  • Editas Medicine
  • Imara
  • Hema Quest Pharmaceuticals
  • Archer Daniels Midland Company
  • Protagonist Therapeutics
  • Fate Therapeutics
  • Celularity
  • Graphite Bio
  • Beam Therapeutics
  • Intellia Therapeutics
  • Silence Therapeutics
  • Agios Pharmaceuticals
  • Forma Therapeutics
  • Vor Biopharma
  • Mast Therapeutics

第九章：关于我们

简介目录
Product Code: GIS31579

Sickle-cell Anemia Therapeutics Market is anticipated to expand from $2.5 billion in 2024 to $5.6 billion by 2034, growing at a CAGR of approximately 10.1%. The Sickle-cell Anemia Therapeutics Market encompasses treatments aimed at managing and alleviating symptoms of sickle-cell disease, including gene therapies, blood transfusions, and pharmacological interventions. This market is driven by advancements in genetic research and increased awareness, with a focus on improving patient outcomes and quality of life. The demand for innovative therapies is rising, propelled by the need for more effective and targeted treatment options.

The Sickle-cell Anemia Therapeutics Market is experiencing robust growth, propelled by advances in gene therapy and pharmaceutical innovations. Gene therapy leads the performance landscape, offering transformative potential by targeting the genetic root of the disease. CRISPR-Cas9 and other genome-editing technologies are at the forefront, promising long-term solutions. The pharmaceutical segment follows closely, with hydroxyurea and voxelotor as key therapeutic agents enhancing patient quality of life. Emerging treatments like L-glutamine and monoclonal antibodies are gaining attention, reflecting ongoing diversification in therapeutic approaches. The bone marrow transplant sub-segment is witnessing renewed interest due to improved success rates and reduced risks. Meanwhile, supportive care therapies, including pain management and blood transfusions, continue to play a vital role in patient management. The integration of digital health solutions, such as telemedicine and patient monitoring apps, is enhancing treatment accessibility and adherence, driving further market growth. Increasing research funding and strategic partnerships are expected to fuel innovation and expand therapeutic options.

Market Segmentation
TypeGene Therapy, Pharmacotherapy, Bone Marrow Transplant
ProductHydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab
TechnologyCRISPR-Cas9, Lentiviral Vectors, RNA Interference
ApplicationPain Management, Blood Transfusion, Stroke Prevention, Acute Chest Syndrome
End UserHospitals, Specialty Clinics, Research Institutes, Homecare
DeploymentOn-Premise, Cloud-Based, Hybrid
StagePreclinical, Clinical Trials, Commercialized
DeviceInfusion Pumps, Blood Transfusion Devices, Diagnostic Equipment
SolutionsPatient Monitoring, Therapeutic Monitoring, Data Analytics

The Sickle-cell Anemia Therapeutics Market is experiencing dynamic shifts in market share, pricing strategies, and product innovations. Pharmaceutical companies are focusing on innovative therapies to address unmet medical needs, leading to a competitive landscape characterized by frequent new product launches. Pricing strategies are increasingly influenced by value-based models, reflecting the growing emphasis on cost-effectiveness and patient outcomes. North America remains a dominant player in the market, with emerging regions witnessing increased interest and investment. Competition benchmarking reveals a market characterized by strategic collaborations and mergers, aimed at enhancing product portfolios and expanding geographical presence. Regulatory influences are pivotal, with stringent guidelines in North America and Europe driving compliance and innovation. Companies are leveraging regulatory frameworks to gain competitive advantages, focusing on accelerated approval pathways for novel therapies. The market is poised for growth, driven by advancements in gene therapy and personalized medicine, despite challenges such as high R&D costs and complex clinical trial processes.

Geographical Overview:

The Sickle-cell Anemia Therapeutics Market is witnessing varied growth patterns across global regions. North America remains at the forefront, propelled by advanced healthcare infrastructure and significant research investments. The presence of leading pharmaceutical companies further underpins market growth in this region. Europe follows, with robust government support for rare disease treatments and a strong focus on innovative therapeutic approaches. In the Asia Pacific, the market is expanding rapidly. This growth is driven by increasing awareness and improved healthcare access. Emerging economies like India and China are investing heavily in healthcare infrastructure, creating new growth pockets. Latin America presents untapped potential, with Brazil leading efforts in improving sickle-cell disease management. Meanwhile, the Middle East & Africa are gradually recognizing the importance of addressing sickle-cell anemia, with countries like Nigeria and South Africa showing increased healthcare initiatives. These regions offer lucrative opportunities for market expansion and investment.

The Sickle-cell Anemia Therapeutics Market is intricately influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea, facing increased tariffs on pharmaceutical imports, are prioritizing domestic R&D investments to mitigate reliance on foreign therapeutics. China's strategic pivot towards self-sufficiency is evident in its robust investment in biopharmaceutical innovation, while Taiwan leverages its advanced biotech capabilities amidst geopolitical tensions. The parent market is witnessing a steady growth trajectory globally, driven by heightened demand for innovative treatment modalities. By 2035, the market is anticipated to flourish, contingent on regional collaborations and supply chain resilience. Middle East conflicts exacerbate global supply chain vulnerabilities and elevate energy prices, indirectly impacting manufacturing costs and distribution timelines in this sector.

Key Trends and Drivers:

The Sickle-cell Anemia Therapeutics Market is experiencing dynamic growth due to increased awareness and advancements in treatment options. One key trend is the development of gene therapies, which offer the potential for a permanent cure. These innovative treatments are gaining traction as they move through clinical trials, promising transformative outcomes for patients. Another significant trend is the rise in collaborations between pharmaceutical companies and research institutions. These partnerships are accelerating the development of novel therapeutics and facilitating faster access to cutting-edge treatments. Furthermore, the increasing prevalence of sickle-cell disease in regions like Sub-Saharan Africa and India is driving demand for effective therapies. Government initiatives and funding are also playing a crucial role in market expansion. Efforts to improve healthcare infrastructure and access to treatments in developing countries are creating new opportunities. Additionally, the growing focus on personalized medicine is fostering the development of targeted therapies, enhancing patient outcomes and market prospects.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Deployment
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Gene Therapy
    • 4.1.2 Pharmacotherapy
    • 4.1.3 Bone Marrow Transplant
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Hydroxyurea
    • 4.2.2 L-Glutamine
    • 4.2.3 Voxelotor
    • 4.2.4 Crizanlizumab
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 CRISPR-Cas9
    • 4.3.2 Lentiviral Vectors
    • 4.3.3 RNA Interference
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Pain Management
    • 4.4.2 Blood Transfusion
    • 4.4.3 Stroke Prevention
    • 4.4.4 Acute Chest Syndrome
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Specialty Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Homecare
  • 4.6 Market Size & Forecast by Deployment (2020-2035)
    • 4.6.1 On-Premise
    • 4.6.2 Cloud-Based
    • 4.6.3 Hybrid
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Preclinical
    • 4.7.2 Clinical Trials
    • 4.7.3 Commercialized
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Infusion Pumps
    • 4.8.2 Blood Transfusion Devices
    • 4.8.3 Diagnostic Equipment
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Patient Monitoring
    • 4.9.2 Therapeutic Monitoring
    • 4.9.3 Data Analytics

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Deployment
      • 5.2.1.7 Stage
      • 5.2.1.8 Device
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Deployment
      • 5.2.2.7 Stage
      • 5.2.2.8 Device
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Deployment
      • 5.2.3.7 Stage
      • 5.2.3.8 Device
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Deployment
      • 5.3.1.7 Stage
      • 5.3.1.8 Device
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Deployment
      • 5.3.2.7 Stage
      • 5.3.2.8 Device
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Deployment
      • 5.3.3.7 Stage
      • 5.3.3.8 Device
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Deployment
      • 5.4.1.7 Stage
      • 5.4.1.8 Device
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Deployment
      • 5.4.2.7 Stage
      • 5.4.2.8 Device
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Deployment
      • 5.4.3.7 Stage
      • 5.4.3.8 Device
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Deployment
      • 5.4.4.7 Stage
      • 5.4.4.8 Device
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Deployment
      • 5.4.5.7 Stage
      • 5.4.5.8 Device
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Deployment
      • 5.4.6.7 Stage
      • 5.4.6.8 Device
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Deployment
      • 5.4.7.7 Stage
      • 5.4.7.8 Device
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Deployment
      • 5.5.1.7 Stage
      • 5.5.1.8 Device
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Deployment
      • 5.5.2.7 Stage
      • 5.5.2.8 Device
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Deployment
      • 5.5.3.7 Stage
      • 5.5.3.8 Device
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Deployment
      • 5.5.4.7 Stage
      • 5.5.4.8 Device
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Deployment
      • 5.5.5.7 Stage
      • 5.5.5.8 Device
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Deployment
      • 5.5.6.7 Stage
      • 5.5.6.8 Device
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Deployment
      • 5.6.1.7 Stage
      • 5.6.1.8 Device
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Deployment
      • 5.6.2.7 Stage
      • 5.6.2.8 Device
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Deployment
      • 5.6.3.7 Stage
      • 5.6.3.8 Device
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Deployment
      • 5.6.4.7 Stage
      • 5.6.4.8 Device
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Deployment
      • 5.6.5.7 Stage
      • 5.6.5.8 Device
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Global Blood Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Emmaus Life Sciences
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 CRISPR Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bluebird Bio
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Sangamo Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Editas Medicine
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Imara
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Hema Quest Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Archer Daniels Midland Company
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Protagonist Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Fate Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Celularity
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Graphite Bio
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Beam Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Intellia Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Silence Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Agios Pharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Forma Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Vor Biopharma
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Mast Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us